SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3138)6/8/2017 5:22:36 PM
From: tuck  Respond to of 3202
 
Navoximod, OTOH, appears to be a direct inhibitor of IDO. Here's the underlying patent app:

Imidazole Derivatives as IDO Inhibitors

Interestingly, in light of Indoximod's MOA, Indoximod and Navoximod were shown to be synergistic at 2013 AACR:

NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy

See the upper right of the poster. Would NLNK try this combo now that they own both?

I understand that losing validation from Genentech is a serious blow, but are these assets as worthless as AF suggests (he wondered why NLNK trades above cash)?

Cheers, Tuck



To: tuck who wrote (3138)6/8/2017 10:14:20 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3202
 
<So, I get what MZ and AF are saying. Indoximod seems to work by by targeting an indirect effect of IDO,...>
Correct, and at 200-2000 mg dose it is more like supplement that enzyme inhibitor. I have no idea how Roche give away $150M for this "krap"?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News